These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8791042)

  • 1. Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group.
    Bono AV; Hall RR; Denis L; Lovisolo JA; Sylvester R
    Eur Urol; 1996; 29(4):385-90. PubMed ID: 8791042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions.
    Oosterlinck W; Bono AV; Mack D; Hall R; Sylvester R; de Balincourt C; Brausi M;
    Eur Urol; 2001 Nov; 40(5):515-7. PubMed ID: 11752858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.
    Kondás J; Kiss L; Határ A; Kiss A; Lukács T; Szeldeli P; Törzsök F; Bodrogi I
    Int Urol Nephrol; 1999; 31(4):451-6. PubMed ID: 10668939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.
    Saika T; Tsushima T; Nasu Y; Miyaji Y; Saegusa M; Takeda K; Kumon H
    World J Urol; 2010 Aug; 28(4):413-8. PubMed ID: 20054553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
    Lindgren MS; Bue P; Azawi N; Blichert-Refsgaard L; Sundelin MO; Dyrskjøt L; Jensen JB
    Eur Urol; 2020 Dec; 78(6):856-862. PubMed ID: 32736928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.
    da Silva FC; Ferrito F; Brandão T; Santos A
    Eur Urol; 1992; 21(1):42-4. PubMed ID: 1606981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
    Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
    Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2012 Nov; 62(5):797-802. PubMed ID: 22633362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
    Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
    J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
    Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
    Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
    Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical chemoresection with 4'-epi-doxorubicin in patients with superficial bladder tumors.
    Calais da Silva F; Denis L; Bono A; Bollack C; Bouffioux C
    Eur Urol; 1988; 14(3):207-9. PubMed ID: 3289935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short schedule intravesical mitomycin preceding transurethral resection for recurrent Ta-T1, G1-G2 bladder cancer.
    Maffezzini M; Simonato A; Lodolo C; Raber M; Carmignani G
    Tumori; 1995; 81(3):191-3. PubMed ID: 7571026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer.
    Bono AV; Lovisolo JA; Saredi G
    Eur Urol; 2000 Apr; 37(4):478-83. PubMed ID: 10765080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.